Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
17 hedge funds and large institutions have $4.58M invested in Aridis Pharmaceuticals Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
156% more capital invested
Capital invested by funds: $1.79M → $4.58M (+$2.79M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
6% more funds holding
Funds holding: 16 → 17 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$7.53K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.77K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.32K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$320 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$51K |
| 2 |
EWA
EP Wealth Advisors
Torrance,
California
|
-$47K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$14.8K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$9.81K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
ARDS Hedge Fund Activity: Q4 2022 in Review
17 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q4 2022, worth a combined $4.58M — up 156% from $1.79M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ARDS positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2M. The largest seller was Citadel Advisors, exiting entirely with an estimated $51K sold.
- 17 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q4 2022, up from 16 in Q3 2022.
- Funds reported $4.58M of Aridis Pharmaceuticals Inc. Common Stock stock for Q4 2022, up 156% quarter-over-quarter.
- 3 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q4 2022 was Armistice Capital, an estimated $2M added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q4 2022 was Citadel Advisors, an estimated $51K sold.
Based on aggregated 13F filings for Q4 2022.